Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical
activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without
Active Proliferative Lupus Nephritis